Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Svetinorm6 residuesAEDLPGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: A-7, KEDA (active component), Livagen (related)
Forty-seven patients with chronic hepatitis and post-chemotherapy liver damage. That's the entire human evidence base for Svetinorm, an oral peptide bioregulator from Russia's Institute of Bioregulation and Gerontology. The peptide complex A-7 contains KEDA (Lys-Glu-Asp-Ala), a tetrapeptide that targets hepatocyte DNA and reactivates age-silenced genes tied to liver detoxification. ALT and bilirubin stabilized by week three in that single study. No randomized controlled trial has followed. Longevity-focused users still run 30-day courses two to three times per year, tracking liver panels to confirm what bloodwork alone can verify.
Svetinorm (peptide complex A-7) is a mixture of low-molecular-weight peptides (under 10 kDa) extracted from young calf liver tissue, designed to support hepatocyte gene expression. Forty-four indexed PubMed citations exist, zero randomized controlled trials, and one clinical study from a single research group. It was developed at the St. Petersburg Institute of Bioregulation and Gerontology by Prof. Vladimir Khavinson, who spent decades building a library of organ-specific bioregulators. The active component is believed to include the tetrapeptide KEDA (Lys-Glu-Asp-Ala), also sold separately as Livagen. How it works at the cellular level is actually well mapped. KEDA penetrates hepatocyte nuclei and binds DNA promoter regions, causing heterochromatin decondensation at ribosomal gene loci on chromosomes 1, 9, and 16. That reactivates genes silenced by age-related chromatin compaction. Downstream, CYP450 phase I enzymes, glutathione S-transferase, and albumin synthesis all increase in preclinical models [1]. The clinical picture is thin. Khavinson's 2003 to 2004 study enrolled 47 patients with chronic hepatitis and post-chemotherapy liver injury. Those receiving Svetinorm showed stabilized ALT and bilirubin, plus decreased IgM [2]. No placebo arm. No blinding. No Western replication. Prof. Khavinson died in January 2024; no new primary research has appeared since. Users who run Svetinorm tend to be longevity enthusiasts already familiar with the Khavinson bioregulator system. Most follow the published protocol exactly: 10 to 20 mg daily for 30 days, off for four to six months, repeated two to three times per year. Without baseline liver panels, distinguishing a real response from placebo is functionally impossible.
KEDA (Lys-Glu-Asp-Ala), the tetrapeptide believed to be Svetinorm's active component, shows tissue-specific affinity for hepatocytes. Once inside the cell, it crosses the nuclear membrane and interacts with DNA promoter regions through complementary binding. This causes local unwinding of the double helix, activating RNA polymerase-driven transcription at sites that had gone quiet. The specific epigenetic change is heterochromatin decondensation. In aged liver cells, ribosomal gene loci on chromosomes 1, 9, and 16 become compacted, silencing protein synthesis. KEDA reverses that compaction, essentially turning those genes back on. Khavinson's group confirmed this in organotypic liver cultures from old rats, where KEDA restored protein synthesis rates to levels comparable to young tissue [1]. Downstream effects are broad. CYP450 phase I detoxification enzymes get upregulated, increasing the liver's capacity to metabolize xenobiotics. Glutathione S-transferase (GST) and UDP-glucuronosyltransferase (UGT) activity increases for phase II conjugation. Albumin output rises. The peptide also modulates hepatocyte growth factor (HGF) receptor expression, which supports liver regeneration after injury [3]. All of this comes from preclinical work. The jump from rat organotypic cultures to human hepatocytes in vivo is large, and no formal pharmacokinetic study has confirmed whether oral KEDA reaches the liver in bioactive concentrations.
Hepatoprotective effects (ALT/bilirubin stabilization, IgM reduction) observed in a single uncontrolled clinical study (n=47, chronic hepatitis and post-chemo populations, Khavinson Institute 2003–2004). Mechanistic data (KEDA epigenetic chromatin remodeling, CYP450/GST upregulation, HGF receptor modulation) supported by in vitro and animal models. No RCTs. No placebo control. No Western replication. Primary investigator deceased Jan 2024; no new primary research published since.
PMID 32362099: "The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology." Adv Gerontol, 2020. Most recent indexed study directly on KEDA/A-7 complex; covers animal hepatitis models and human aging data.
No RCTs. No blinding or placebo control in the clinical study. Single research group (Khavinson Institute). Proprietary A-7 composition not publicly disclosed. No formal PK data for KEDA or Svetinorm. No Western-journal clinical trials. Primary investigator (Khavinson) deceased Jan 2024; new research pipeline stalled. Aggressive tier (40 mg/day) exceeds conservative Firma Vita maximum of 2 caps 2x daily.
Niche use confined to longevity and Khavinson bioregulator enthusiasts. Subjective reports of improved energy and digestion during the 30-day course. Too few independent user reports to characterize effect reliability. Community confidence largely derived from the Khavinson clinical literature rather than independent user experience.
Community dosing and stated outcomes closely mirror the Khavinson Institute protocol: because most users derive their approach directly from that literature rather than independent experimentation. True independent alignment cannot be confirmed given the near-zero community self-report pool. The agreement is methodological (adopting the published protocol) rather than empirical (independent verification of outcomes).
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 10mg | 2x Daily |
| Aggressive | 20mg | 2x Daily |
Svetinorm ships as oral capsules. No reconstitution, no syringes, no bacteriostatic water. Each capsule contains 10 mg of peptide complex A-7. Bottles come in 20-cap and 60-cap sizes. A 60-cap bottle covers one full 30-day course at 2 caps per day. The 20-cap bottle only lasts 10 days at that dose, so you'll need three of them for a complete course. Take capsules with meals. The manufacturer and the Khavinson protocol both specify mealtime dosing; empty-stomach use is the main trigger for the mild GI discomfort some users report. Get a liver panel (ALT, AST, bilirubin) before your first capsule. Get another at the end of the 30-day course. Without those two data points, you're flying blind on whether anything actually changed. The off-period matters. Four to six months between courses is not a suggestion; it's the core premise of the bioregulator approach. KEDA triggers epigenetic changes that are supposed to persist after the compound clears. Restarting early undermines the protocol's theoretical basis.
Standard Khavinson bioregulator protocol: 20-30 days on, then off for 4-6 months. Repeat 2-3 times per year. The long off-period allows endogenous regulatory mechanisms to stabilize. Limited data on optimal cycling duration.
The Khavinson protocol's 4–6 month off-period is based on bioregulator theory: short peptides (KEDA) trigger epigenetic changes (heterochromatin decondensation, ribosomal gene reactivation, and upregulation of liver-specific transcription) that persist after the compound clears. Long off-periods allow these epigenetic gains to consolidate and endogenous regulatory mechanisms to stabilize. This rationale is distinct from receptor desensitization, antibody formation, or hormonal axis recovery. The 30-day course length and multi-month off-period are derived from Khavinson's empirical institutional protocols, not from published PK/PD optimization studies.
Or use the universal Peptide Calculator for any peptide.
Expected: Possible ALT and bilirubin stabilization measurable on bloodwork by week 2–3 (primarily in individuals with elevated baseline liver enzymes); subtle energy and digestive improvement; no dramatic subjective response expected in healthy individuals
Monitor: Obtain baseline ALT, AST, and bilirubin before starting. Retest at end of the 30-day course. No objective bloodwork improvement after one course warrants reassessment before repeating.
Request ALT, AST, and total bilirubin from your physician or a direct-to-consumer lab. Record your results before starting.
Open the bottle and take 1 capsule (10 mg) with your largest meal on Day 1. This is a tolerance check. Swallow whole with water.
From Day 2 onward, take 1 capsule (10 mg) twice daily with meals (breakfast and dinner) for the standard protocol. For the conservative maintenance tier, 1 capsule once daily is sufficient.
A 60-capsule bottle covers a full 30-day course at 2 capsules per day.
No reconstitution. No refrigeration required during the course. Store capsules at room temperature (15 to 25 degrees Celsius) in a dry place away from direct sunlight.
Compare ALT, AST, and bilirubin to baseline values. No measurable change after one course is common in healthy individuals; changes are more detectable if baseline values were raised.
Plan 2 to 3 courses per year. Do not restart early.
No published pharmacokinetic comparison between oral capsule and sublingual form; same dose convention (10 mg units) used by vendors offering the sublingual format
Sublingual form sold by vita-stream.com and QiSupplements.com ("EternaPeptix A-7"). Some community members prefer it on the theory that sublingual absorption bypasses first-pass hepatic metabolism and increases bioavailability of small peptides. No PK study has been published comparing the two routes for Svetinorm or KEDA. The standard oral capsule form is the only route with any clinical study backing.
Standard Khavinson full-body longevity stack. Pineal (Epithalon) + liver (Svetinorm) is the most common two-organ Khavinson bioregulator pairing. Courses are typically run sequentially, not simultaneously.
Part of the Khavinson multi-organ bioregulator system. Cognitive and neuroendocrine support alongside the liver peptide protocol; commonly used in a sequential full-body annual bioregulator cycle.
Thymic bioregulator in the Khavinson system. Immune + liver co-support is a common pairing for multi-organ Khavinson protocols. Sequential dosing is typical.
Complementary hepatoprotective with stronger Western RCT evidence. Svetinorm (epigenetic/transcriptional) + glutathione (antioxidant/detox) address distinct liver protection mechanisms and can be run concurrently.
Svetinorm reduced IgM (an immune marker) in the Khavinson clinical study. Combining with immunosuppressants in transplant recipients is theoretically risky and insufficiently studied.
Do not combineNSAIDs are among the most common causes of drug-induced liver injury. Concurrent use adds hepatotoxic burden during a liver-support protocol.
Statins carry hepatotoxic risk (transaminase elevation); monitoring liver enzymes is especially important if combining with Svetinorm.
KEDA tetrapeptide has shown effects on blood clotting and fibrinolysis in preclinical models; theoretical interaction with anticoagulant therapy. No clinical data to characterize the risk.
Pricing updated 2026-04-09
The safety dataset for Svetinorm is too small to characterize a reliable side-effect profile. The entire human evidence base comes from one uncontrolled clinical study of 47 patients at the Khavinson Institute (2003 to 2004), plus a near-zero pool of independent community reports. That is not enough to detect rare adverse events. No serious adverse effects were documented in the available literature. The clinical study reported no treatment-related safety signals in either the chronic hepatitis or post-chemotherapy cohorts. Community users on Longecity forums and practitioner blogs consistently describe the product as well tolerated. But "no reports" from a sample this small is not the same as "safe." Mild digestive discomfort is the only side effect mentioned with any consistency. A few users noted GI sensitivity during the first two to three days when capsules were taken on an empty stomach. Taking Svetinorm with meals appears to resolve this, and the manufacturer's instructions specify mealtime dosing. The KEDA tetrapeptide showed effects on blood clotting and fibrinolysis in preclinical models. Anyone taking anticoagulants (warfarin, heparin) should flag this to their physician. No clinical data exists to quantify the interaction risk, but the preclinical signal warrants caution. Svetinorm reduced IgM levels in the clinical study, which is a marker of immune activity. For transplant recipients on immunosuppressants like cyclosporine or tacrolimus, this creates a theoretical additive immunosuppressive effect. That combination has not been studied and should be avoided without specialist oversight. Liver function worsening has not been documented, but the entire premise of taking a liver bioregulator assumes you're monitoring liver function. If ALT or AST rise during or after a course, stop and consult a hepatologist. Pregnancy and breastfeeding are contraindicated. No reproductive safety data exists. Children under 14 have not been studied. Anyone with active liver failure or decompensated cirrhosis lacks data to support use in that population. The honest summary: Svetinorm appears well tolerated in limited observation, but the observation is genuinely limited. Bloodwork before and after each course is the only way to catch a problem early.
Verify Svetinorm dosing and safety with a second opinion
Oral capsules from a Russian manufacturer (Firma Vita / St. Petersburg Institute of Bioregulation and Gerontology). The legitimate product has a 30+ year institutional track record. Western buyers face supply chain opacity: gray-market resellers on eBay and Amazon present authenticity and handling-compliance risks. No independent third-party COA testing infrastructure exists for this product category comparable to Western dietary supplement standards.
| Test | When | Target |
|---|---|---|
| ALT (Alanine Aminotransferase) | Baseline before each course; end of 30-day course; optional 3-month post-course | <40 U/L (normal); response defined as trend toward normal from an elevated baseline |
| AST (Aspartate Aminotransferase) | Baseline before each course; end of 30-day course | <40 U/L (normal) |
| Total Bilirubin | Baseline before each course; end of 30-day course | 0.1–1.2 mg/dL (normal) |
| IgM (Immunoglobulin M) | Optional; baseline and end of course if monitoring inflammatory status | — |
Primary endpoint in the Khavinson clinical study; key marker for hepatoprotective effect. Required to distinguish real response from placebo.
Companion liver enzyme marker; helps distinguish hepatocellular injury from biliary or other causes
Second primary endpoint in Khavinson study; elevated bilirubin indicates hepatocyte dysfunction; stabilization expected during course in disease populations
Decreased IgM was an observed secondary outcome in the Khavinson hepatitis study, indicating anti-inflammatory activity; not a standard liver panel component
No noticeable external changes expected. Peptide-DNA interactions begin at the cellular level. Gene transcription changes are accumulating in hepatocytes but won't be perceptible.
Some users anecdotally report improved energy and digestion. In the clinical study, biochemical markers (ALT, bilirubin) began stabilizing during this phase. Effects are subtle and difficult to distinguish from placebo.
End of standard on-cycle. The clinical study showed measurable stabilization of liver enzymes and decreased IgM levels by this point. Improvements in liver function tests may be confirmable via bloodwork.
Bioregulator theory holds that epigenetic changes persist after discontinuation. Liver enzyme levels should remain stable. Plan the next course for 4-6 months later.
Days 1 through 7: Nothing perceptible. KEDA-DNA interactions are initiating inside hepatocytes, and heterochromatin at ribosomal gene loci on chromosomes 1, 9, and 16 is starting to decondense. CYP450 and GST transcription changes accumulate silently. Mild GI sensitivity is possible if you skip the "with meals" instruction. Most users report exactly zero changes during this window. Weeks 2 through 3: The clinical study data picks up here. ALT and bilirubin began stabilizing in the hepatitis and post-chemotherapy patients by this phase [2]. Some community users mention improved energy and appetite, though these reports are subtle and hard to separate from placebo without bloodwork. Protein synthesis upregulation is accumulating in hepatocytes, but you won't feel that directly. Week 4 (end of course): The finish line for a standard on-cycle. The Khavinson study showed measurable ALT, bilirubin stabilization, and decreased IgM by this point, but only in populations that started with abnormal baselines. Healthy individuals may see no detectable shift on bloodwork. Get your post-course liver panel now. Months 2 through 6 (off-cycle): Bioregulator theory holds that the epigenetic changes, chromatin remodeling and transcription activation, persist after the peptide clears. Liver enzyme improvements should hold through the off-period. Subjective effects gradually return toward baseline for most users. Plan the next course at the four to six month mark. Do not restart early.
KEDA-DNA interactions initiating in hepatocytes; heterochromatin decondensation at ribosomal gene loci (chromosomes 1, 9, 16) beginning; CYP450 and GST transcription changes accumulating: no detectable biochemical shift at this stage
Nothing noticeable; occasional mild GI sensitivity in the first 2–3 days if taken without food
ALT and bilirubin stabilization begins in hepatitis/post-chemo populations based on Khavinson 2003 data; protein synthesis upregulation accumulating in hepatocytes
Some users report improved energy and appetite; effects are subtle and easily confounded with placebo without baseline bloodwork comparison
ALT and bilirubin stabilization, and decreased IgM, observed by this point in Khavinson clinical study (disease populations only). Healthy-individual biochemical response unknown.
Subjective energy improvement may persist; users encouraged to get a post-course liver panel to confirm objective response
Bioregulator theory: chromatin remodeling and transcription activation persist after peptide clearance; liver enzyme improvements expected to be maintained through the off-period without additional dosing
Subjective effects return toward baseline gradually; most users plan the next course at 4–6 months and do not experience relapse of symptoms during the off-period
Source: Estimated from tetrapeptide class pharmacokinetics. No direct PK study exists for Svetinorm or KEDA. Short peptides (2-4 amino acids) are rapidly degraded by peptidases within minutes to an hour.
Loading the interactive decay curve.
Svetinorm is classified as a dietary supplement (parafarmacy product) in Russia, where it has been manufactured and sold by Firma Vita for over 30 years under the institutional backing of the St. Petersburg Institute of Bioregulation and Gerontology. It is not FDA-approved in the United States and holds no regulatory status from the EMA in Europe. In the U.S., Svetinorm occupies a gray zone. It is imported and sold by specialty vendors as a dietary supplement or research product. It is not scheduled, not controlled, and not prohibited for personal importation. However, it has not undergone FDA review for safety, efficacy, or manufacturing standards. WADA status: not listed as a prohibited substance. Athletes should verify current WADA and sport-specific anti-doping lists before use, as bioregulator peptides are a category that could attract future scrutiny. Sourcing transparency is a real concern. Legitimate product comes from Firma Vita. Resellers on eBay and Amazon often cannot verify provenance. Purchase from documented importers only. This content is for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide. Peptide Schedule does not sell peptides or endorse specific suppliers.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
